R 80122

structure given in first source; inhibits cyclic nucleotide phosphodiesterase type III; RN given refers to the E- isomer; R 79595 has no isomeric designation; R 80123 is the Z-isomer

Also Known As:

R 79595; R 80123; R-79595; R-80122; R-80123; R80122; Acetamide, N-cyclohexyl-N-methyl-2-(((phenyl(1,2,3,5-tetrahydro-2-oxoimidazo(2,1-b)quinazolin-7-yl)methylene)amino)oxy)-, (E)-

Networked: 9 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - R 80122: 9
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - R 80122: 9

Related Diseases

1.	Heart Failure 03/01/1992 - "It may be concluded that R 80122 has a clinically favorable cardiovascular profile for acute applications in heart failure, because its combined positive inotropic and positive lusitropic effects, and moderate vasodilating properties lead to a pronounced increase in cardiac output and only minimal changes in aortic blood pressure." 03/01/1992 - "This pronounced lusitropic effect of R 80122 can be regarded as beneficial, because of the increasing evidence that lusitropic defects play an important role in disorders related to heart failure. " 01/01/1992 - "R 80122 enhanced cardiac contractility at lower concentrations than milrinone with no concomitant increase in frequency or shortening of the action potential, which may be advantageous for treatment of heart failure." 07/01/1992 - "Intravenous infusion of the compounds (0.005 mg/kg/min for both) was started when stable heart failure had developed and was continued for 50 min followed by a washout period of 60 min. Both R80122 and milrinone improved the function of the acutely failing heart, as indicated by the increase in the values of the variables related to left ventricular function, but differences existed. " 07/01/1992 - "The cardiac and hemodynamic effects of R80122, a new specific phosphodiesterase III inhibitor, were studied in a closed-chest canine model of acute global left ventricular ischemia complicated by heart failure. "
2.	Heart Diseases (Heart Disease) 06/01/1995 - "The aim of this study was to compare the haemodynamic effects of enoximone and R80122 in patients with ischaemic heart disease. "
3.	Coronary Artery Disease (Coronary Atherosclerosis) 12/01/1994 - "The present study was designed to compare the effects of enoximone and R 80122, a highly selective phosphodiesterase (PDE) III inhibitor, on left ventricular hemodynamics and myocardial blood flow and metabolism in patients with coronary artery disease. "
4.	Myocardial Ischemia (Ischemic Heart Diseases) 07/01/1992 - "Cardiac and hemodynamic effects of intravenous R80122, a new phosphodiesterase III inhibitor, in a canine model of myocardial ischemia and heart failure." 12/01/1994 - "Effects of enoximone and R 80122, a new selective phosphodiesterase III inhibitor, on hemodynamics and myocardial energetics in patients with ischemic heart disease."
5.	Left Ventricular Dysfunction 06/01/1995 - "Hemodynamic effects of the novel selective cAMP-phosphodiesterase III inhibitor R 80122 in anesthetized patients with moderate left ventricular dysfunction before coronary artery bypass grafting."

Related Drugs and Biologics

1.	Milrinone (Primacor)
2.	Enoximone
3.	Phosphoric Diester Hydrolases (Phosphodiesterases)
4.	Type 3 Cyclic Nucleotide Phosphodiesterases
5.	R 80122
6.	3',5'-Cyclic-AMP Phosphodiesterases (3',5' Cyclic Nucleotide Phosphodiesterase)
7.	Phosphodiesterase Inhibitors
8.	Isoenzymes
9.	Hexobarbital (Hexenal)
10.	Anti-Arrhythmia Agents

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)